Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethanesulfonic Acid Amide SCHEMBL1607974 | 0.94 | SLC22A12 (0.43) | SLC22A12HPGDMAPTL3MBTL1KDM4E | |
| SCHEMBL856308 | 0.81 | PIK3CB (0.54) | SLC22A12ALPL | |
| SCHEMBL18595672 | 0.80 | SLC22A12 (0.48) | SLC22A12HPGDMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL16913769 | 0.79 | SLC22A12 (0.42) | SLC22A12HPGDMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL23563123 | 0.79 | HPGD (0.46) | HPGDMAPTL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL28850792 | 0.79 | HPGD (0.42) | HPGDMAPTL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL30043814 | 0.79 | HPGD (0.42) | HPGDMAPTL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL3093140 | 0.77 | ALDH1A1 (0.47) | SLC22A12HPGDSMN1; SMN2HTTLMNA | |
| SCHEMBL3119732 | 0.77 | SLC22A12 (0.46) | SLC22A12MAPTKDM4ESMN1; SMN2POLB | |
| SCHEMBL17996191 | 0.76 | NR3C2 (0.44) | SLC22A12HPGDMAPTL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2701512-B1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2701512-B1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9073929-B2 | Aldosterone synthase inhibitors | ELEXOPHARM GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073929-B2 | Aldosterone synthase inhibitors | ELEXOPHARM GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| CN-102459247-B | benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2014-09-17 | — | — | CN | disclosed |
| WO-2014106800-A2 | SUBSTITUTED 2-AMINO PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-10 | — | — | WO | disclosed |
| WO-2014106800-A2 | SUBSTITUTED 2-AMINO PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-10 | — | — | WO | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| EP-2430018-B1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| CN-102459247-A | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2012-05-16 | — | — | CN | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| EP-2430018-A2 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | Novartis AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130773-A2 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B2, CYP11B1, CYP21A2 | SLC22A12 1843/4885HPGD 96/4885MAPT 3928/4885 |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP17A1, HSD11B1 | SLC22A12 2336/4885HPGD 220/4885MAPT 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.